Martin Pule
Overview
Explore the profile of Martin Pule including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
4686
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferrari M, Parekh F, Maciocia P, Horna P, Thomas S, Sewell A, et al.
Nat Commun
. 2025 Jan;
16(1):1103.
PMID: 39880830
No abstract available.
2.
Manipadam M, Marra A, Ramsay A, Padmasri S, Gosh A, Neves M, et al.
Hematol Oncol
. 2024 Dec;
43(1):e70018.
PMID: 39655706
No abstract available.
3.
Roddie C, Sandhu K, Tholouli E, Logan A, Shaughnessy P, Barba P, et al.
N Engl J Med
. 2024 Nov;
391(23):2219-2230.
PMID: 39602653
Background: Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persistence. Methods: We conducted...
4.
Cwynarski K, Iacoboni G, Tholouli E, Menne T, Irvine D, Balasubramaniam N, et al.
Nat Med
. 2024 Nov;
31(1):137-143.
PMID: 39528665
Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely...
5.
Ferrari M, Righi M, Baldan V, Wawrzyniecka P, Bulek A, Kinna A, et al.
Nat Commun
. 2024 Feb;
15(1):1583.
PMID: 38383515
Peripheral T cell lymphomas are typically aggressive with a poor prognosis. Unlike other hematologic malignancies, the lack of target antigens to discriminate healthy from malignant cells limits the efficacy of...
6.
Jha R, Kinna A, Hotblack A, Bughda R, Bulek A, Gannon I, et al.
ACS Chem Biol
. 2024 Jan;
19(2):308-324.
PMID: 38243811
A versatile, safe, and effective small-molecule control system is highly desirable for clinical cell therapy applications. Therefore, we developed a two-component small-molecule control system based on the disruption of protein-protein...
7.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, et al.
Mol Ther
. 2023 Dec;
32(2):556-558.
PMID: 38103549
No abstract available.
8.
Woodruff R, Parekh F, Lamb K, Mekkaoui L, Allen C, Smetanova K, et al.
Mol Ther Methods Clin Dev
. 2023 Oct;
31:101123.
PMID: 37886606
Base editing is a revolutionary gene-editing technique enabling the introduction of point mutations into the genome without generating detrimental DNA double-stranded breaks. Base-editing enzymes are commonly delivered in the form...
9.
Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A, et al.
Blood
. 2023 Aug;
143(2):118-123.
PMID: 37647647
CD19-negative relapse is a leading cause of treatment failure after chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia. We investigated a CAR T-cell product targeting CD19 and CD22...
10.
Anderson N, Birch J, Accogli T, Criado I, Khabirova E, Parks C, et al.
Nat Med
. 2023 Jul;
29(7):1700-1709.
PMID: 37407840
In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of...